Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.

Pawlitzki M, Sweeney-Reed CM, Meuth SG, Reinhold D, Neumann J.

PLoS One. 2018 Nov 26;13(11):e0207726. doi: 10.1371/journal.pone.0207726. eCollection 2018.

2.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2018 Nov 16. doi: 10.1007/s00415-018-9117-z. [Epub ahead of print]

PMID:
30446966
3.

Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.

Pawlitzki M, Uebelhör J, Sweeney-Reed CM, Stephanik H, Hoffmann J, Lux A, Reinhold D.

Nutrients. 2018 Jul 26;10(8). pii: E967. doi: 10.3390/nu10080967.

4.

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab.

Pawlitzki M, Teuber J, Campe C, Wagner M, Schuart C, Paul F, Bittner D.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 9;5(5):e475. doi: 10.1212/NXI.0000000000000475. eCollection 2018 Sep. No abstract available.

5.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

6.

Loss of corticospinal tract integrity in early MS disease stages.

Pawlitzki M, Neumann J, Kaufmann J, Heidel J, Stadler E, Sweeney-Reed C, Sailer M, Schreiber S.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e399. doi: 10.1212/NXI.0000000000000399. eCollection 2017 Nov.

7.

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports.

Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze HJ, Matzke M, Mawrin C, Rommer P, Kovacs GG, Mitter C, Reindl M, Brück W, Wandinger KP, Lassmann H, Höftberger R, Leypoldt F.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335. doi: 10.1212/NXI.0000000000000335. eCollection 2017 May. No abstract available.

Supplemental Content

Loading ...
Support Center